Jubilant Pharmova Ltd (BOM:530019)

₹ 719.3 -13.5 (-1.84%) Market Cap: 113.90 Bil Enterprise Value: 138.50 Bil PE Ratio: 148.31 PB Ratio: 2.10 GF Score: 82/100

Q3 2023 Jubilant Pharmova Ltd Earnings Call Transcript
Feb 03, 2023

₹343.85 (-1.24%)

Earnings
Q2 2023 Jubilant Pharmova Ltd Earnings Call Transcript
Oct 21, 2022

₹340.6 (+5.29%)

Earnings
Q1 2023 Jubilant Pharmova Ltd Earnings Call Transcript
Aug 02, 2022

₹361.05 (-2.81%)

Earnings
Q4 2022 Jubilant Pharmova Ltd Earnings Call Transcript
May 27, 2022

₹404.3 (+1.81%)

Earnings
Q3 2022 Jubilant Pharmova Ltd Earnings Call Transcript
Feb 04, 2022

₹526.4 (+0.40%)

Earnings
Q2 2022 Jubilant Pharmova Ltd Earnings Call Transcript
Oct 22, 2021

₹604.1 (-1.25%)

Earnings
Q1 2022 Jubilant Pharmova Ltd Earnings Call Transcript
Jul 23, 2021

₹696.9 (-2.59%)

Earnings
Jubilant Pharmova Ltd Investor & Analyst Meet Transcript
Jun 18, 2021
Q3 2021 Jubilant Life Sciences Ltd Earnings Call Transcript
Feb 05, 2021

₹935.15 (+2.88%)

Earnings
Q2 2021 Jubilant Life Sciences Ltd Earnings Call Transcript
Nov 04, 2020

₹528.79 (+1.50%)

Earnings
Q1 2021 Jubilant Life Sciences Ltd Earnings Call Transcript
Sep 04, 2020

₹620.74 (+1.33%)

Earnings
Q4 2020 Jubilant Life Sciences Ltd Earnings Call Transcript
May 29, 2020

₹330.91 (+1.73%)

Earnings
Jubilant Life Sciences Limited - Special Call Transcript
Apr 01, 2020
Q3 2020 Jubilant Life Sciences Ltd Earnings Call Transcript
Jan 31, 2020

₹435.44 (-3.55%)

Earnings
Q2 2020 Jubilant Life Sciences Ltd Earnings Call Transcript
Oct 25, 2019

₹420.03 (-1.45%)

Earnings
Q1 2020 Jubilant Life Sciences Ltd Earnings Call Transcript
Jul 26, 2019

₹333.61 (-0.22%)

Earnings
Q4 2019 Jubilant Life Sciences Ltd Earnings Call Transcript
May 17, 2019

₹445.99 (-4.09%)

Earnings

Q3 2021 Jubilant Life Sciences Ltd Earnings Call Transcript

Feb 05, 2021 / 11:30AM GMT

Release Date Price: ₹935.15 (+2.88%)

Transcript

Operator

Ladies and gentlemen, good day, and welcome to Jubilant Pharmova Limited, earlier known as Jubilant Life Sciences Limited, Q3 and 9 Months FY '21 Earnings Conference Call. (Operator Instructions) There will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Hemant Bakhru, Head, Investor Relations. Thank you, and over to you, Mr. Bakhru.

Hemant Bakhru

Jubilant Pharmova Limited - Head of IR

Thank you. Good evening, everyone. Thank you for being with us on our Q3 FY '21 earnings conference call.

Please note, effective 1st February 2021, the Life Sciences Ingredients business stands demerged into Jubilant Ingrevia Limited and has been classified as discontinued operations in Q3 results. Further, the name of Jubilant Life Sciences has been changed to Jubilant Pharmova Limited effective 1st February 2021.

I would like to remind you that some of the statements made on the call today

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.